A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
← catalyst calendarSponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →. With Gilead Sciences.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
94actual
Sites
22
Countries
Poland, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-19 | actual | When the study began enrolling |
| Primary completion | 2025-08-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-25 | actual | The whole study's end, after follow-up |
| First posted | 2021-02-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Non Small Cell Lung Cancer (NSCLC)
- Melanoma
- Cervical Cancer
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma (DLBCL)
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
Interventions
- Drug: AB308
- Drug: Zimberelimab — also filed as AB122
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with Adverse Events
measured From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
Percentage of participants who experience a Dose Limiting Toxicity
measured From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm) or Day 42 (Q6W arm)
Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed